ReviewNature reviews. Gastroenterology & hepatology2021
Regulation and functional roles of chemokines in liver diseases.
Review in Nature reviews. Gastroenterology & hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 98 citations in OpenAlex.
- Serum CC-Chemokine Profiling in Alcohol-Associated Liver Disease: Focus on MIP-3α/CCL20 as a Biomarker of Disease Severity.Diagnostics (Basel, Switzerland) · 2026Article
- Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma.Journal for immunotherapy of cancer · 2026Article
- A pathogenic CD8⁺ TNature communications · 2026Article
- Reprogramming macrophages to treat liver diseases.Hepatology (Baltimore, Md.) · 2026Review
- Molecular Mechanism of POSTN Mediating M2 Polarization of Kupffer Cells to Promote Hepatic Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Hepatocyte-targeted Bap1 reduction in the liver primes an inflammatory transcriptional response.G3 (Bethesda, Md.) · 2026Article
- Hepatic glutathione depletion ameliorates MASLD through selective protein oxidation and inhibition of lipogenesis.The Journal of clinical investigation · 2026Article
- Uncovering potentially targetable genes in liver fibrosis via bioinformatics and experimental validation.Scientific reports · 2026Article
- Single cell multiomic landscape reveals gene programs driving lipid droplet heterogeneity in hepatic steatosis.Scientific reports · 2026Article
- Therapeutic potential of tetrahydroxylated bile acids in reducing liver injury: Insights from thePediatric investigation · 2026Article
- Rumen microbiota modulates metabolic stress in high-yield dairy cows: insights from early to peak lactation.Microbiome · 2026Article
- Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases.Signal transduction and targeted therapy · 2026Review
- ScRNA-seq Identifies High CXCL8 Linked to Liver Fibrosis in HBeAg-negative Chronic Hepatitis B Patients With Low HBsAg.Gastro hep advances · 2026Article
- Bisphenol F and Steatotic Liver Disease: Resolving the PXR Paradox Through Stress Pathway Mechanisms.Biomedicines · 2025Review
- Cytoprotective effect of prostacyclin on hepatic ischemia-reperfusion injury.World journal of methodology · 2025Review
- Intravenous Lidocaine Modulates the Perioperative Hepatic Inflammatory Response: Implications for Personalized Medicine in Thoracic Surgery.Journal of personalized medicine · 2025Article
- Diagnostic and Prognostic Potential of CXCL9 and CXCL10 Chemokines in Alcohol-Associated Liver Disease.International journal of molecular sciences · 2025Observational
- Hepatocyte iron suppresses liver fibrosis via fibrolytic neutrophil recruitment in cholestasis.JHEP reports : innovation in hepatology · 2025Article
- Anti-inflammatory effects of palm11-PrRP31 in a rat model of lipopolysaccharide-induced acute inflammation.Journal of molecular endocrinology · 2025Article
- Biomimetic Vascularized iPSC-Hepatocyte Spheroids for Liver Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammation is a major contributor to the pathogenesis of almost all liver diseases. Low-molecular-weight proteins called chemokines are the main drivers of liver infiltration by immune cells such as macrophages, neutrophils and others during an inflammatory response. During the past 25 years, tremendous progress has been made in understanding the regulation and functions of chemokines in the liver. This Review summarizes three main aspects of the latest advances in the study of chemokine function in liver diseases. First, we provide an overview of chemokine biology, with a particular focus on the genetic and epigenetic regulation of chemokine transcription as well as on the cell type-specific production of chemokines by liver cells and liver-associated immune cells. Second, we highlight the functional roles of chemokines in liver homeostasis and their involvement in progression to disease in both human and animal models. Third, we discuss the therapeutic opportunities targeting chemokine production and signalling in the treatment of liver diseases, such as alcohol-associated liver disease and nonalcoholic steatohepatitis, including the relevant preclinical studies and ongoing clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.